Androgen receptor as a potential sign of prostate cancer metastasis

Prostate

Volumn 69, Issue 15, 2009, Pages 1704-1711

  Lévesque, Marie Hélène ^a   El Alfy, Mohamed ^a   Cusan, Leonello ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgens; Immunohistochemistry; In situ hybridization; Mitochondrial marker; Prostatic intraepithelial neoplasia (PIN)

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS POTENTIAL; MITOCHONDRION; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADENOCARCINOMA; AGED; BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 70349587428     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21021     Document Type: Article

References (35)

1. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8(3):338-362.
2. Labrie F, Bélanger A, Candas B, Cusan L, Gomez JL, Labrie C, Luu-The V, Simard J. GnRH agonists in the treatment of prostate cancer. Endocr Rev 2005;26(3):361-379.
3. Labrie F. Endocrinology and the prostate. Preface. Best Pract Res Clin Endocrinol Metab 2008;22(2):vii-ix.
4. Perez CA, Fair WR, Ihde DC, F L. Cancer of the prostate. Cancer, principles and practice of oncology. Philadelphia: Lippincott; pp. 929-964.
5. Azzi L, El-Alfy M, Labrie F. Gender differences and effects of sex steroids and dehydroepiandrosterone on androgen and oestrogen alpha receptors in mouse sebaceous glands. Br J Dermatol 2006;154(1):21-27. (Pubitemid 43381315)
6. Leav I, McNeal JE, Kwan PW, Komminoth P, Merk FB. Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: An immunohistochemical and in situ hybridization study. Prostate 1996; 29(3):137-145. (Pubitemid 26341818)
7. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001;159(1):79-92. (Pubitemid 33704195)
8. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 1999;140(3):1481-1491. (Pubitemid 29104255)
9. Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, Loda M. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 1997;10(8):839-845. (Pubitemid 27374856)
10. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 1999;161(4):1229-1232. (Pubitemid 29426123)
11. Cardillo MR, Petrangeli E, Salvatori L, Ravenna L, Di Silverio F. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia. Anal Quant Cytol Histol 2000;22(5):403-410. (Pubitemid 30776681)
12. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992;147(3 Pt 2):798-803.
13. Masai M, Sumiya H, Akimoto S, Yatani R, Chang CS, Liao SS, Shimazaki J. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 1990;17(4):293-300.
14. Levesque MH, El-Alfy M, Berger L, Labrie F, Labrie C. Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases. Urology 2007;69(1):196-201. (Pubitemid 46161716)
15. Solakidi S, Psarra AM, Nikolaropoulos S, Sekeris CE. Estrogen receptors alpha and beta (ERalpha and ERbeta) and androgen receptor (AR) in human sperm: Localization of ERbeta and AR in mitochondria of the midpiece. Hum Reprod 2005;20(12):3481-3487. (Pubitemid 41742531)
16. Jagla M, Feve M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat JP, Ceraline J. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007;148(9):4334-4343. (Pubitemid 47295699)
17. Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Begin LR, Mes-Masson AM, Saad F. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: Potential implications for prostate cancer development and prognosis. BJU Int 2008;101(10):1302-1309. (Pubitemid 351549633)
18. Scheller K, Sekeris CE, Krohne G, Hock R, Hansen IA, Scheer U. Localization of glucocorticoid hormone receptors in mitochondria of human cells. Eur J Cell Biol 2000;79(5):299-307. (Pubitemid 30345276)
19. Mao P, Nakao K, Angrist A. Human prostatic carcinoma: An electron microscope study. Cancer Res 1966;26(5):955-973.
20. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975;2(1):105-124.
21. Tacha DE, Chen T. Modified antigen retrieval procedure: Calibration technique for microwave ovens. J Histotechnol 1994;17:365.
22. Kramer CY. Extension of multiple range tests to group means with unique numbers of replications. Biometrics 1956;12:307-310.
23. Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Cancer Invest 2007;25(1):32-37. (Pubitemid 46423588)
24. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 2000;14(8):1162-1174. (Pubitemid 32260478)
25. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, Marcelli M, Weigel NL, Mancini MA. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet 1999;8(5):731-741. (Pubitemid 29189040)
26. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001;61:423-427. (Pubitemid 32128590)
27. Schafer W, Funke PJ, Kunde D, Rausch U, Wennemuth G, Stutzer H. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: Correlation with clinical data of long-term observations. J Urol 2006;176(2):532-537. (Pubitemid 43927890)
28. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology 2007;70(6):1225-1229. (Pubitemid 350297391)
29. Morgan EA, Forootan SS, Adamson J, Foster CS, Fujii H, Igarashi M, Beesley C, Smith PH, Ke Y. Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: Potential prognostic marker and target for tumourigenicity-suppression. Int J Oncol 2008;32(4):767-775. (Pubitemid 351780587)
30. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002;62(3):854-859. (Pubitemid 34126964)
31. Madsen P, Rasmussen HH, Leffers H, Honore B, Celis JE. Molecular cloningand expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol 1992;99(3):299-305.
32. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59(1):10-16. (Pubitemid 43076233)
33. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287(13):1662-1670. (Pubitemid 34289218)
34. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: Genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004;64(17):5963-5972. (Pubitemid 39129392)
35. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;191(2):125-135.